A Phase I trial evaluating XmAb-20717, a PD-1 x CTLA-4 dual checkpoint inhibitor for the treatment of multiple oncology indications.

Trial Profile

A Phase I trial evaluating XmAb-20717, a PD-1 x CTLA-4 dual checkpoint inhibitor for the treatment of multiple oncology indications.

Planning
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs XmAb-20717 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jan 2018 New trial record
    • 05 Jan 2018 According to a Xencor media release, the company is planning to initiate this trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top